

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human OCTN2/SLC22A5 in ELISA.
<b>Source</b>	Monoclonal Mouse IgG <sub>2A</sub> Clone # 893753
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	NS0 transfected with human SLC22A5 Accession # O76082
<b>Conjugate</b>	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
<b>Formulation</b>	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the Technical Information section on our website.

<b>Flow Cytometry</b>	Titration recommended for optimal concentration with starting range of 0.1-1 µg/1 million cells. Sample used for this experiment was HEK293 Human Cell Line Transfected with Human OCTN2/SLC22A5 and eGFP
-----------------------	---

## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> • 12 months from date of receipt, 2 to 8 °C as supplied.

## BACKGROUND

Polyspecific organic cation transporters in the liver, kidney, intestine, and other organs are critical for the elimination of many endogenous small organic cations as well as a wide array of drugs and environmental toxins. SLC22A5 is an integral plasma membrane protein which functions as an organic cation transporter and as a sodium-dependent high affinity carnitine transporter. Mutations in SLC22A5 are the cause of systemic primary carnitine deficiency (CDSP), an autosomal recessive disorder manifested early in life by hypoketotic hypoglycemia and acute metabolic decompensation, and later in life by skeletal myopathy or cardiomyopathy.

## PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.